Full Text View
Tabular View
No Study Results Posted
Related Studies
Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)
This study has been completed.
Study NCT00034853   Information provided by Boehringer Ingelheim Pharmaceuticals

First Received on May 2, 2002.   Last Updated on May 11, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Arthritis, Juvenile Rheumatoid
Additional conditions recognized in this trial
Arthritis
Arthritis, Rheumatoid
More general conditions related to this trial
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Interventions listed in this trial
meloxicam oral suspension
naproxen oral suspension
Additional drug interventions recognized in this trial
Meloxicam
Naproxen
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Gout Suppressants
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Boehringer Ingelheim Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services